Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Myeloma Immunoglobulin Idiotype VaccineDrug: BortezomibDrug: CyclophosphamideBiological: GMCSF (granulocyte macrophage colony stimulating factor)Drug: CyclosporineDrug: Doxorubicin hydrochlorideDrug: EtoposideDrug: Fludarabine phosphateDrug: PrednisoneDrug: Vincristine SulfateDrug: MethotrexateBiological: GCSF (granulocyte colony stimulating factor)
- First Posted Date
- 2000-08-24
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00006184
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia
- Conditions
- Fanconi's Anemia
- First Posted Date
- 2000-06-05
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 30
- Registration Number
- NCT00005898
- Locations
- ๐บ๐ธ
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 105
- Registration Number
- NCT00001586
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
- Conditions
- MelanomaNeoplasm Metastasis
- Interventions
- Drug: IL-2Procedure: ApheresisBiological: Abl cellsDrug: Montanide ISA-51Drug: FludarabineDrug: CyclophosphamideBiological: GCSF (Growth colony stimulating factor)
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 170
- Registration Number
- NCT00001832
- Locations
- ๐บ๐ธ
National Cancer Institute (NCI), Bethesda, Maryland, United States
Bone Marrow Transplantation in Treating Children With Sickle Cell Disease
- Conditions
- Sickle Cell Anemia
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2008-09-10
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00004485
- Locations
- ๐บ๐ธ
Children's Hospital of Oakland, Oakland, California, United States
๐บ๐ธFred Hutchinson Cancer Research Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.